A Phase 1B Clinical Trial to Examine the Role of Host Genetics in Determining the Immune Response to HIV Vaccination (With VRC-HIVDNA016-00-VP and VRC-HIVADV014-00-VP) in Twin Pairs.
Phase of Trial: Phase I
Latest Information Update: 23 Jun 2016
At a glance
- Drugs VRC-HIVADV014-00-VP (Primary) ; VRC-HIVDNA016-00-VP (Primary)
- Indications HIV infections
- Focus Pharmacodynamics; Pharmacogenomic
- 10 Jun 2017 Biomarkers information updated
- 20 Jun 2016 Status changed from active, no longer recruiting to completed.
- 02 Apr 2012 Actual patient number changed from 160 to 8 as reported by ClinicalTrials.gov.